

Clinical trials of azimilide

TrialResults-center www.trialresultscenter.org

1 post myocardial infarction

| Trial | Treatments | Patients | Trials design and methods |
|---|---------------------------------------|-------------------------------------|---------------------------------|
| azimilide vs placebo | | | |
| ALIVE , 2004 n=NA follow-up: 1y | azimilide 100 mg versus placebo | post-MI patients with depressed LVF | Parallel groups double blind |

More details and results :

- antiarrhythmic drugs for post myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q251>

References

ALIVE, 2004:

Pratt CM, Singh SN, Al-Khalidi HR, Brum JM, Holroyde MJ, Marcello SR, Schwartz PJ, Camm AJ The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. J Am Coll Cardiol 2004 Apr 7;43:1211-6 [[15063432](#)]

Camm AJ, Pratt CM, Schwartz PJ, Al-Khalidi HR, Spyt MJ, Holroyde MJ, Karam R, Sonnenblick EH, Brum JM Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 2004 Mar 2;109:990-6 [[14967728](#)]

Camm AJ, Karam R, Pratt CM The azimilide post-infarct survival evaluation (ALIVE) trial. Am J Cardiol 1998 Mar 19;81:35D-39D [[9537221](#)]

2 atrial fibrillation

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|---------------------------------|
| Azimilide vs placebo | | | |
| ASAP , 2003 n=891/489 follow-up: 6 months | Azimilide various doses (35 to 125 mg/d) after pharmacological or electrical cardioversion versus placebo | patients with previous AF documented in the last 2 years | Parallel groups double blind |

More details and results :

- antiarrhythmic drugs for atrial fibrillation in maintaining sinus rhythm after cardioversion at <http://www.trialresultscenter.org/go-Q113>

References

ASAP, 2003:

Connolly SJ, Schnell DJ, Page RL, Wilkinson WE, Marcello SR, Pritchett EL Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. *Am J Cardiol* 2001;88:974-9 [[11703992](#)]

Connolly SJ, Schnell DJ, Page RL, Wilkinson WE, Marcello SR, Pritchett EL Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials. *Am Heart J* 2003;146:489-93 [[12947368](#)]

Page RL, Tilsch TW, Connolly SJ, Schnell DJ, Marcello SR, Wilkinson WE, Pritchett EL Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide. *Circulation* 2003;107:1141-5 [[12615792](#)]

Pritchett EL, Page RL, Connolly SJ, Marcello SR, Schnell DJ, Wilkinson WE Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. *J Am Coll Cardiol* 2000;36:794-802 [[10987602](#)]

Page RL, Connolly SJ, Wilkinson WE, Marcello SR, Schnell DJ, Pritchett EL Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response. *Am Heart J* 2002;143:643-9 [[11923801](#)]

Entry terms: Azimilide